Zambia has yet to sign a bilateral health memorandum of understanding with the United States, a delay that stems from disagreements over data and specimen sharing rather than mineral access, officials said.
Negotiations focus on data and specimen terms
During a Zoom interview with Managed Healthcare Executive before the closing session of the 26th International AIDS Conference in Rio de Janeiro, Lloyd Mulenga, director of infectious diseases at the Zambia Ministry of Health, explained the three‑part structure of the pending agreement. The core health component outlines joint financing of programs, while the data‑sharing clause would require Zambia to transmit program and performance‑based health metrics to U.S. partners. Mulenga noted that this element forces the country to balance its own data protection laws against the United States’ request for detailed information.
Specimen sharing, the third pillar, raises similar concerns. “What are the benefits to the country for specimen sharing? If we share the specimens, what will the benefits? If vaccines are developed from the specimens shared from Zambia, will Zambia have access to those? So those are I think those are the thorny issues,” he said. The discussion hinges on whether Zambia would gain access to any vaccines or therapeutics derived from domestically collected biological material and how intellectual property rights would be allocated.
According to the outlet, 33 nations have already signed similar memoranda under the Trump administration’s America First Global Health Strategy, which aims to shift U.S. foreign aid toward mutually financed health projects. Zambia remains among the few still negotiating, and its position reflects broader debates at the World Health Organization about equitable benefit sharing.
Related: User Account Blocked by Social Media Platform
Potential impact on Zambia’s health sector
If finalized, the agreement could bring new resources for disease surveillance and treatment programs, but the trade‑off involves ceding some control over data and biological samples. The health ministry must consider whether the promised access to vaccines outweighs possible constraints on domestic research autonomy. The lack of a signed MOU also means the country continues to rely on traditional aid channels, which may be less predictable under shifting U.S. policy.
Mulenga’s remarks suggest that Zambia is looking for concrete returns, such as guaranteed vaccine supplies or technology transfer, before committing to share specimens. The negotiation process appears to be a balancing act between national sovereignty and the desire for advanced medical interventions.
From a broader perspective, Zambia’s hesitation mirrors past attempts by low‑ and middle‑income nations to negotiate terms that protect local interests while engaging with powerful partners. Similar stalemates have occurred in other sectors where data sovereignty and benefit sharing are contentious, indicating that the health MOU may set a precedent for future agreements.
Officials said no final decision has been made, and discussions are ongoing.
